Abstract
PALB2 interacts with BRCA2, and biallelic mutations in PALB2 (also known as FANCN), similar to biallelic BRCA2 mutations, cause Fanconi anemia. We identified monoallelic truncating PALB2 mutations in 10/923 individuals with familial breast cancer compared with 0/1,084 controls (P = 0.0004) and show that such mutations confer a 2.3-fold higher risk of breast cancer (95% confidence interval (c.i.) = 1.4–3.9, P = 0.0025). The results show that PALB2 is a breast cancer susceptibility gene and further demonstrate the close relationship of the Fanconi anemia–DNA repair pathway and breast cancer predisposition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Xia, B. et al. Mol. Cell 22, 719–729 (2006).
Reid, S. et al. Nat. Genet. advance online publication 31 December 2006 (doi:10.1038/ng1947).
The Breast Cancer Linkage Consortium. J. Natl. Cancer Inst. 91, 1310–1316 (1999).
Meijers-Heijboer, H. et al. Nat. Genet. 31, 55–59 (2002).
Renwick, A. et al. Nat. Genet. 38, 873–875 (2006).
Seal, S. et al. Nat. Genet. 38, 1239–1241 (2006).
Xia, B. et al. Nat. Genet. advance online publication 31 December 2006 (doi: 10.1038/ng1942).
Taniguchi, T. & D'Andrea, A.D. Blood 107, 4223–4233 (2006).
Howlett, N.G. et al. Science 297, 606–609 (2002).
Reid, S. et al. J. Med. Genet. 42, 147–151 (2005).
Levitus, M. et al. Nat. Genet. 37, 934–935 (2005).
Levran, O. et al. Nat. Genet. 37, 931–933 (2005).
Seal, S. et al. Cancer Res. 63, 8596–8599 (2003).
Antoniou, A.C. & Easton, D.F. Oncogene 25, 5898–5905 (2006).
Shiloh, Y. Trends Biochem. Sci. 31, 402–410 (2006).
Acknowledgements
We thank the participating families who were recruited to the study by the Familial Breast Cancer Collaboration (UK) which includes the following contributors: A. Ardern-Jones, J. Berg, A. Brady, N. Bradshaw, C. Brewer, G. Brice, B. Bullman, J. Campbell, B. Castle, R. Cetnarsryj, C. Chapman, C. Chu, N. Coates, T. Cole, R. Davidson, A. Donaldson, H. Dorkins, F. Douglas, D. Eccles, R. Eeles, F. Elmslie, D.G. Evans, S. Goff, S. Goodman, D. Goudie, J. Gray, L. Greenhalgh, H. Gregory, N. Haites, S.V. Hodgson, T. Homfray, R.S. Houlston, L. Izatt, L. Jeffers, V. Johnson-Roffey, F. Kavalier, C. Kirk, F. Lalloo, I. Locke, M. Longmuir, J. Mackay, A. Magee, S. Mansour, Z. Miedzybrodzka, J. Miller, P. Morrison, V. Murday, J. Paterson, M. Porteous, N. Rahman, M. Rogers, S. Rowe, S. Shanley, A. Saggar, G. Scott, L. Side, L. Snadden, M. Steel, M. Thomas and S. Thomas. We thank A. Hall and E. Mackie for coordination of sample collection. We acknowledge use of DNA from the British 1958 Birth Cohort collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. P.K. is supported by a grant from the Breast Cancer Campaign. A.E. is supported by US Army Medical Research and Material Command grant W81XWH-05-1-0204. This research was supported by donations from the Geoffrey Berger and Daniel Falkner Charitable Trusts, by the Institute of Cancer Research and by Cancer Research UK.
Author information
Authors and Affiliations
Consortia
Contributions
The study was designed by N.R. and M.R.S. The molecular analyses were performed by S.S., P.K., A.R., S.R., K.S., R.B., T.C., H.J. and S.H. under the direction of N.R. The statistical analyses were performed by D.T., A.E. and L.M. under the direction of D.F.E. The familial collections were initiated by D.G.E. and D.E. and were collected by the Breast Cancer Susceptibility Collaboration (UK). The manuscript was written by N.R. and M.R.S.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
FANCN (also known as PALB2) nontruncating coding variants. (PDF 51 kb)
Rights and permissions
About this article
Cite this article
Rahman, N., Seal, S., Thompson, D. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39, 165–167 (2007). https://doi.org/10.1038/ng1959
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1959
This article is cited by
-
Cascade screening in HBOC and Lynch syndrome: guidelines and procedures in a UK centre
Familial Cancer (2024)
-
Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis
Breast Cancer Research and Treatment (2023)
-
Breast cancer in the era of integrating “Omics” approaches
Oncogenesis (2022)
-
Detection of a pathogenic Alu element insertion in PALB2 gene from targeted NGS diagnostic data
European Journal of Human Genetics (2022)
-
30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes
European Journal of Human Genetics (2022)